TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical DetectionMarket Beat·Aug 17 at 09:02 PMMASS+3.19%
908 Devices CEO Kevin J. Knopp disposes of USD 283,477.32 in common sharesPUBT·Aug 17 at 04:31 PMMASS+3.19%
908 Devices Eyes Growth in Handheld Drug and Chemical Detection MarketMarket Beat·Aug 15 at 02:01 AMMASS+3.19%
908 Devices CEO Kevin J. Knopp disposes of USD 1.46 million in common sharesPUBT·Aug 12 at 04:05 PMMASS+3.19%
908 Devices CEO, CFO to present at Midwest IDEAS Investor ConferencePUBT·Aug 12 at 06:00 AMMASS+3.19%
SNG: Revenue, earnings, and order intake surged in H1 2026, with outlook and margins improvingQuartr·Aug 12 at 01:14 AMSNG
908 Devices forecasts 2026 revenue from continuing operations of $68 million to $70 millionPUBT·Aug 11 at 06:20 AMMASS+3.19%
MASS: 23% Q2 revenue growth, 57% adjusted gross margin, and strong cash position drive outlookQuartr·Aug 11 at 06:10 AMMASS+3.19%
908 Devices | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 16.07 MEarnings Watch·Aug 11 at 06:07 AMMASS+3.19%
908 Devices Q2 FY26 adjusted EBITDA loss narrows 50% to $1.9 million; revenue rises 23% to $16.1 millionPUBT·Aug 11 at 06:02 AMMASS+3.19%
